Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Glen Eagle Advisors LLC

Glen Eagle Advisors LLC decreased its holdings in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 35.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,691 shares of the medical research company's stock after selling 4,678 shares during the period. Glen Eagle Advisors LLC's holdings in Edwards Lifesciences were worth $643,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of EW. Vanguard Group Inc. grew its stake in shares of Edwards Lifesciences by 10.4% during the fourth quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company's stock worth $5,117,845,000 after purchasing an additional 6,537,494 shares in the last quarter. Wellington Management Group LLP grew its stake in shares of Edwards Lifesciences by 5.3% during the fourth quarter. Wellington Management Group LLP now owns 33,210,879 shares of the medical research company's stock worth $2,458,601,000 after purchasing an additional 1,678,154 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Edwards Lifesciences by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 13,647,341 shares of the medical research company's stock worth $1,007,520,000 after purchasing an additional 126,194 shares in the last quarter. Fisher Asset Management LLC grew its stake in shares of Edwards Lifesciences by 7.7% during the fourth quarter. Fisher Asset Management LLC now owns 9,775,276 shares of the medical research company's stock worth $723,664,000 after purchasing an additional 696,965 shares in the last quarter. Finally, Norges Bank acquired a new position in shares of Edwards Lifesciences during the fourth quarter worth $610,895,000. Institutional investors and hedge funds own 79.46% of the company's stock.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, CEO Bernard J. Zovighian sold 6,164 shares of the stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $69.51, for a total transaction of $428,459.64. Following the transaction, the chief executive officer now owns 59,083 shares of the company's stock, valued at $4,106,859.33. This trade represents a 9.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Daniel J. Lippis sold 400 shares of the stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $69.48, for a total transaction of $27,792.00. Following the transaction, the vice president now directly owns 22,588 shares in the company, valued at approximately $1,569,414.24. This represents a 1.74% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 66,192 shares of company stock valued at $4,709,454. Company insiders own 1.29% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on EW shares. Truist Financial reduced their price target on shares of Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating for the company in a research report on Friday, April 11th. Stifel Nicolaus raised shares of Edwards Lifesciences from a "hold" rating to a "buy" rating and upped their target price for the company from $75.00 to $90.00 in a report on Thursday, January 30th. Robert W. Baird upped their target price on shares of Edwards Lifesciences from $72.00 to $75.00 and gave the company a "neutral" rating in a report on Thursday, April 24th. StockNews.com cut shares of Edwards Lifesciences from a "buy" rating to a "hold" rating in a report on Friday, May 16th. Finally, Barclays upped their target price on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the company an "overweight" rating in a report on Thursday, February 13th. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eleven have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $79.60.

Edwards Lifesciences Stock Down 0.3%

Shares of NYSE EW opened at $77.82 on Wednesday. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $95.25. The company has a market capitalization of $45.65 billion, a PE ratio of 11.16, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The firm's 50-day moving average is $72.47 and its two-hundred day moving average is $71.90.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.60 by $0.04. The company had revenue of $1.41 billion for the quarter, compared to the consensus estimate of $1.40 billion. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. The company's revenue for the quarter was up 6.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.66 earnings per share. Equities analysts anticipate that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.